Novartis said its experimental drug atrasentan was shown to have a positive effect on an indicator of kidney health in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial.
Proteinuria is excess protein in the urine, which can be a sign of the kidney failing to filter properly. The trial will continue with more read-outs on kidney function expected in the first quarter of 2026, the company added.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: